Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from CalciMedica ( (CALC) ).
On November 6, 2025, CalciMedica, Inc. announced an increase in the maximum aggregate offering price of its common stock from $4,450,000 to $9,700,000 under its at-the-market offering agreement with H.C. Wainwright & Co. This adjustment reflects the company’s strategic move to bolster its financial resources, potentially enhancing its market position and providing greater flexibility in pursuing its operational goals.
The most recent analyst rating on (CALC) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on CalciMedica stock, see the CALC Stock Forecast page.
Spark’s Take on CALC Stock
According to Spark, TipRanks’ AI Analyst, CALC is a Underperform.
CalciMedica’s low stock score reflects its financial challenges, including zero revenue and negative cash flows. However, technical indicators suggest the stock is currently oversold, providing a potential entry point for risk-tolerant investors. The promising results from the Auxora trial offer a positive outlook, potentially improving future financial performance.
To see Spark’s full report on CALC stock, click here.
More about CalciMedica
CalciMedica, Inc. operates in the biotechnology industry, focusing on developing therapies for acute inflammatory diseases.
Average Trading Volume: 51,375
Technical Sentiment Signal: Sell
Current Market Cap: $42.62M
See more data about CALC stock on TipRanks’ Stock Analysis page.